Polymorphic form of pyrrole derivative and intermediate thereof
The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.
1. A process for the preparation of an amorphous form of saroglitazar magnesium of Formula (I),
the process comprising:
(a) reacting a hydroxy compound (A) with a mesylate compound (A1) in a mixture of cyclohexane and tetrahydrofuran in the presence of a base to obtain an alkoxy ester compound of Formula (II),
(b) hydrolyzing the alkoxy ester compound of Formula (II) with a base in one or more organic solvents to obtain a reaction mixture,
(c) washing the reaction mixture with water and one or more organic solvents, and obtaining a separated aqueous layer,
(d) treating the separated aqueous layer with a magnesium source to obtain a saroglitazar magnesium solution,
(e) removing water from the solution to obtain a saroglitazar magnesium residue; and
(f) adding one or more anti-solvent to the residue followed by removal of anti-solvent to obtain the amorphous form of saroglitazar magnesium of Formula (I).
2. The process according to claim 1 , wherein the anti-solvent comprises one or more of pentane, hexane, heptane, cyclohexane, tetrahydrofuran, 1,4-dioxane, diisopropyl ether, diethyl ether, and methyl tertbutyl ether.
3. The process according to claim 1 , wherein the base in step (a) comprises one or more of sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydride, potassium tert-butoxide, and sodium pentoxide.
4. The process according to claim 1 , wherein the magnesium source in step (d) comprises one or more of magnesium hydroxide, magnesium methoxide, magnesium acetate, magnesium chloride, and magnesium metal.